Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease

Movement Disorders

Volumn 17, Issue 6, 2002, Pages 1227-1234

  McColl, Craig D ^a   Reardon, Katrina A ^a   Shiff, Mark ^a   Kempster, Peter A ^a  

^a MONASH MEDICAL CENTRE   (Australia)

Author keywords

Dyskinesia; Levodopa; Motor fluctuations; Parkinson's disease

Indexed keywords

CABERGOLINE; CARBIDOPA PLUS LEVODOPA; ENTACAPONE; LEVODOPA; PERGOLIDE;

ADULT; AGED; BALANCE DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; DYSKINESIA; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GAIT DISORDER; HUMAN; LONGITUDINAL STUDY; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; ON OFF PHENOMENON; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SPEECH DISORDER; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; FOLLOW-UP STUDIES; FUNCTIONAL LATERALITY; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR ACTIVITY; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 0036869650     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10244     Document Type: Review

References (34)

1. Marsden CD, Parkes JD, Quinn N. Fluctuations in disability in Parkinson's disease-clinical aspects. In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterworth International Medical Reviews; 1982. p 96-112.
2. Marsden CD. Problems with long-term L-dopa therapy for Parkinson's disease. Clin Neuropharmacol 1994;17:S32-S34.
3. Hughes AJ, Daniel SE, Kifford L, Lees AJ. Accuracy of clinical diagnosis in idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
4. Kempster PA, Frankel JP, Bovingdon M, Webster R, Lees AJ, Stern GM. Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry 1989;52:718-723.
5. Reardon KA, Shiff M, Kempster PA. Motor fluctuations in Parkinson's disease: a longitudinal study over 6 years. Mov Disord 1999;14:605-611.
6. Hughes AJ, Frankel JP, Kempster PA, Stern GM, Lees AJ. Motor response to L-dopa in patients with parkinsonian motor fluctuations. J Neurol Neurosurg Psychiatry 1994;57:430-434.
7. Folstein MF, Robins LN, Helzer JE. The Mini-Mental State Examination. Arch Gen Psychiatry 1983;40:812.
8. Sahai H, Thompson W. Comparisons of approximation to the percentile of t, c2 and F distributions. J Stat Comput Simul 1974;3:81-93.
9. Parkinson Study Group. Mortality in DATATOP: a multicentre trial in early Parkinson's disease. Ann Neurol 1998;43:318-325.
10. Hely MA, Morris JGL, Traficante R, Reid WGJ, O'Sullivan DJ, Williamson PM. The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999;67:300-307.
11. Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y. Ten-year follow-up of three different initial treatment, in de-novo Parkinson's disease: a randomized trial. Neurology 2001;57:1687-1694.
12. Shaw KM, Lees AJ, Stern GM. The impact of treatment with L-dopa in Parkinson's disease. Q J Med 1980;195:283-293.
13. 123I]IPT and single-photon emission tomography. Eur J Nucl Med 1997;24:68-71.
14. 11C]raclopride. Mov Disord 1997;12:33-38.
15. Gibb WR, Lees AJ. The progression of idiopathic Parkinson's disease is not explained by age-related changes. Clinical and pathological comparisons with post-encephalitic parkinsonian syndrome. Acta Neuropathol 1987;73:195-201.
16. Mann DM, Yates PO. Pathological basis for neurotransmitter changes in Parkinson's disease. Neuropathol Appl Biol 1983;9:3-19.
17. Gibb WR, Lees AJ. Anatomy, pigmentation, ventral, and dorsal subpopulations in the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:388-396.
18. Nutt JG, Carter JC, Woodward WR. The long duration response to L-dopa. Neurology 1995;45:1613-1616.
19. Hogl B, Gomez-Arevalo G, Garcia S, Scipioni O, Rubio M, Blanco M, Gershanik OS. A clinical, pharmacological, and polysomnographic study of sleep benefit in Parkinson's disease. Neurology 1998:50:1332-1339.
20. Bateman DE, Levett K, Marsden CD. Sleep benefit in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:384-385.
21. Schwab RS. Akinesia paradoxica. Electroencephalogr Clin Neurophysiol 1972;31(Suppl.):87-92.
22. Schwab RS, Zeiper I. Effects of mood, motivation, stress and alertness on the performance in Parkinson's disease. Psychiatr Neurol (Basel) 1965;150:345-357.
23. Ogashara S, Nishakawa Y, Takahashi M, Wada K, Nakamura Y, Yorifuji S, Tarui S. Dopamine metabolism in the central nervous system after discontinuation Of L-dopa therapy in patients with Parkinson's disease. J Neurol Sci 1984;66:151-163.
24. Nutt JG, Carter JC, Woodward WR. Effect of brief L-dopa holidays on the short duration response to L-dopa: evidence for tolerance to the antiparkinsonian effects. Neurology 1994;44:1617-1622.
25. Cotzias GC, Papavasiou PS, Gellene R. Modification of parkinsonism: chronic treatment with L-dopa. N Engl J Med 1969;280:337-345.
26. Nutt JG, Holford HG. The response to L-dopa in Parkinson's disease: imposing pharmacological law and order. Neurology 1996;39:561-573.
27. Fabbrini G, Juncos J, Mouradian MM, Serati C, Chase TN. L-dopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21:370-376.
28. Nutt JG, Carter JH. Apomorphine can sustain the long duration response to L-dopa in fluctuating Parkinson's disease. Neurology 2000;54:247-250.
29. Hauser RA, Koller WC, Hubble JP, Malapira T, Busenbark K, Olanow CW. Time course of loss of clinical benefit after withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. Mov Disord 2000;15:485-489.
30. Babato L, Stocchi F, Monge A, Vacca L, Ruggieri S, Nordera G, Marsden CD. The long-duration action of L-dopa may be due to a post-synaptic effect. Clin Neuropharmacol 1997;20:394-401.
31. Stocchi F, Vacca L, Beradelli A, De Pandis F, Ruggieri S. Long-duration effect and the post-synaptic compartment. Mov Disord 2001;16:301-305.
32. Bunney BS, Aghajanian GK, Roth RH. Comparison of effects of L-dopa, amphetamine and apomorphine in firing rate of rat dopaminergic neurones. Nat New Biol 1973;26:123-125.
33. Agid Y, Javoy F, Glowinski J. Hyperactivity in remaining dopaminergic neurons after partial destruction of the nigrostriatal dopaminergic system in the rat. Nat New Biol 1973;245:150-151.
34. Bonnet A-M, Loria Y, Saint-Hilaire M-H, Lhermitte F, Agid Y. Does long-term aggravation of Parkinson's disease result from non-dopaminergic lesions? Neurology 1987;37:1539-1542.